Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Among authors: laban s. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
5-Aza-2'-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells.
Fehn A, von Witzleben A, Grages A, Kors TA, Ezić J, Betzler AC, Brunner C, Schuler PJ, Theodoraki MN, Hoffmann TK, Laban S. Fehn A, et al. Among authors: laban s. Neoplasia. 2025 Jan;59:101086. doi: 10.1016/j.neo.2024.101086. Epub 2024 Nov 27. Neoplasia. 2025. PMID: 39608124 Free PMC article.
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves GV, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Delord JP, Mesia R, Taberna M, Waldron J, Simon C, Gregoire V, Harrington K, Black CM, Norquist JM, Wang A, Gumuscu B, Bidadi B, Siu LL. Machiels JP, et al. Among authors: laban s. Front Oncol. 2025 Oct 6;15:1645509. doi: 10.3389/fonc.2025.1645509. eCollection 2025. Front Oncol. 2025. PMID: 41122636 Free PMC article.
Co-Stimulatory and Immune Checkpoint Molecule Expression on Peripheral Immune Cells Differs Age Dependently Between Healthy Donors and Patients with Head and Neck Squamous Cell Carcinoma.
Puntigam LK, Grages A, Vahl JM, Oliveri F, Brand M, Laban S, Greve J, Theodoraki MN, Brunner C, Hoffmann TK, Schuler PJ, Von Witzleben A. Puntigam LK, et al. Among authors: laban s. Cancers (Basel). 2025 Oct 2;17(19):3215. doi: 10.3390/cancers17193215. Cancers (Basel). 2025. PMID: 41097741 Free PMC article.
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.
Even C, Harrington KJ, Massarelli E, Laban S, Fayette J, Oliva M, Klein Hesselink M, Visscher S, Fury MG, Wiekmeijer AS, Licitra L, Melichar B, Devriese LA, Braña I, Jankowska P, Posner M, Glisson B, Kong A, Hooftman L, Melief CJM MD,, Ferrarotto R. Even C, et al. Among authors: laban s. J Immunother Cancer. 2025 Sep 8;13(9):e012555. doi: 10.1136/jitc-2025-012555. J Immunother Cancer. 2025. PMID: 40921630 Free PMC article. Clinical Trial.
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.
Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W, Chernock R, Tahara M, Harrington KJ, Klochikhin AL, Braña I, Vasconcelos Alves G, Hughes BGM, Oliva M, Pinto Figueiredo Lima I, Ueda T, Rutkowski T, Schroeder U, Mauz PS, Fuereder T, Laban S, Oridate N, Popovtzer A, Mach N, Korobko Y, Costa DA, Hooda-Nehra A, Rodriguez CP, Bell RB, Manschot C, Benjamin K, Gumuscu B, Adkins D; KEYNOTE-689 Investigators. Uppaluri R, et al. Among authors: laban s. N Engl J Med. 2025 Jul 3;393(1):37-50. doi: 10.1056/NEJMoa2415434. Epub 2025 Jun 18. N Engl J Med. 2025. PMID: 40532178 Clinical Trial.
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Cohen RB; INTERLINK-1 investigators. Fayette J, et al. Clin Cancer Res. 2025 Jul 1;31(13):2617-2627. doi: 10.1158/1078-0432.CCR-25-0073. Clin Cancer Res. 2025. PMID: 40300079 Free PMC article. Clinical Trial.
178 results